Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multiple-Dose, Open-Label Study to Determine and Compare Plasma and Intrapulmonary Concentrations of WCK 5222 (Cefepime and Zidebactam) in Healthy Adult Human Subjects

Trial Profile

A Phase 1, Multiple-Dose, Open-Label Study to Determine and Compare Plasma and Intrapulmonary Concentrations of WCK 5222 (Cefepime and Zidebactam) in Healthy Adult Human Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Aug 2018

At a glance

  • Drugs Cefepime/zidebactam (Primary)
  • Indications Gram-negative infections
  • Focus Pharmacokinetics
  • Sponsors Wockhardt Ltd
  • Most Recent Events

    • 25 May 2018 New trial record
    • 12 May 2018 Results published in the Antimicrobial Agents and Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top